Gazyva 1000mg Solution for Infusion

Introduction

Gazyva is a prescription medication that contains the active ingredient Obinutuzumab. It is available in the form of a solution and is used for the treatment of certain types of cancer.

Uses

Gazyva is primarily prescribed for the treatment of chronic lymphocytic leukemia (CLL) and follicular lymphoma. It is used in combination with other chemotherapy medications to help slow down the growth of cancer cells and improve the overall response to treatment.

Dosage and Administration

The dosage of Gazyva may vary depending on the specific condition being treated and individual patient factors. It is administered by a healthcare professional through a vein (intravenous infusion). The infusion is usually given over several hours, and the frequency of treatment may vary. Follow the dosage instructions provided by your healthcare provider.

Mechanism of Action

Obinutuzumab, the active ingredient in Gazyva, is a type of medication called a monoclonal antibody. It works by targeting and attaching to specific proteins on the surface of cancer cells, which helps the body’s immune system recognize and destroy these cells. This mechanism of action helps to slow down the growth of cancer cells and reduce the spread of the disease.

Side Effects

Common side effects may include infusion-related reactions, such as fever, chills, nausea, and fatigue. Serious side effects, although rare, may include severe allergic reactions, infections, and low blood cell counts. If you experience any severe or persistent side effects, seek medical attention immediately.

Drug Interactions

inform your healthcare provider about all the medications you are currently taking, including prescription drugs, over-the-counter medications, and herbal supplements. Some medications may interact with Gazyva, potentially affecting its effectiveness or increasing the risk of side effects. Your healthcare provider will assess and monitor for any potential drug interactions to ensure your safety and optimize treatment outcomes.

Precautions

Before starting treatment with Gazyva, inform your healthcare provider about any existing medical conditions, including allergies, infections, or a history of heart problems. This medication may not be suitable for everyone, and your healthcare provider will evaluate the potential risks and benefits before initiating treatment. Avoid live vaccines during treatment with Gazyva, as it may interfere with the body’s response to the vaccine.

Storage

Patient Tips

• attend all scheduled appointments for Gazyva infusions as directed by your healthcare provider.
• Stay well-hydrated before and after the infusion to help minimize the risk of certain side effects.
• If you experience any unusual or concerning symptoms during or after the infusion, such as difficulty breathing, severe rash, or chest pain, seek immediate medical attention.
• Follow any additional instructions provided by your healthcare provider regarding dietary restrictions or lifestyle modifications during treatment.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Obinutuzumab (Drugs.com) [Accessed 11 Jun. 2024] (online) Available at:
• obinutuzumab solution (RX) [Accessed 14 Jun. 2024] (online) Available at:
• Obinutuzumab Injection (MedlinePlus) [Accessed 21 Jun. 2024] (online) Available at:
• Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2. [Accessed 11 Jun. 2024] Available at: